Publications by authors named "Sofia De la Villa"
Article Synopsis
- The study assesses how effective short courses of treatment are for patients with carbapenemase-producing Enterobacterales bloodstream infections (CPE-BSI) between 2014 and 2022.
- It includes 105 patient episodes, dividing them into two groups: those receiving treatment for 3-10 days (short treatment group) and those treated for over 10 days (long treatment group).
- Results indicate no significant differences in outcomes between the two groups, suggesting that short treatment durations can be effective if the treatment is appropriate and source control is achieved.
Objectives: To evaluate the impact of time to results (TTR) on the outcome of patients with carbapenemase-producing Enterobacterales bloodstream infections (CPE-BSI).
Methods: Times-series study conducted from January 2014 to December 2021, selecting patients with first CPE-BSI episodes. Periods of intervention were defined according to implementation of diagnostic bundle tests in the microbiology laboratory: pre-intervention (January 2014-December 2017) and post-intervention (January 2018-December 2021).
COVID-19 associated infections in the ICU setting: A retrospective analysis in a tertiary-care hospital.
Enferm Infecc Microbiol Clin (Engl Ed)
May 2023
Introduction: Our work describes the frequency of superinfections in COVID-19 ICU patients and identifies risk factors for its appearance. Second, we evaluated ICU length of stay, in-hospital mortality and analyzed a subgroup of multidrug-resistant microorganisms (MDROs) infections.
Methods: Retrospective study conducted between March and June 2020.
Introduction And Aim: Dalbavancin is an antibiotic with activity against gram-positive bacteria that allows early discharge of patients requiring intravenous therapy. Outpatient treatment helps offset hospitalisation costs associated with standard intravenous treatment. Our objective was to assess the cost of disease management, including treatment with dalbavancin, in a Spanish hospital for 1 year, and the hypothetical costs associated with treatment with other therapeutic alternatives to dalbavancin.
View Article and Find Full Text PDFBackground: We aimed to describe the frequency of use and effectiveness of bezlotoxumab (BZX) and fecal microbiota transplantation (FMT) in patients with infection (CDI) in real-world practice.
Methods: This was a retrospective study conducted in a university hospital in which adult patients treated with BZX or FMT from January 2018 to April 2021 were included. The primary objective was to evaluate the effectiveness of BZX and FMT in preventing early (within 8 weeks) and late (within 1 year) CDI recurrences (rCDI).
Article Synopsis
- Infective Endocarditis (IE) is a serious illness, and diabetes mellitus (DM) has been linked to worse outcomes for patients with IE.
- A study analyzing data from the Spanish IE Registry (2008−2020) found that almost 30% of IE patients had DM, with higher in-hospital and one-year mortality rates for those with DM compared to those without.
- The presence of organ damage in DM patients further increases the risks of mortality, indicating that diabetes management is crucial for improving prognosis in these patients.
Introduction: Our work describes the frequency of superinfections in COVID-19 ICU patients and identifies risk factors for its appearance. Second, we evaluated ICU length of stay, in-hospital mortality and analyzed a subgroup of multidrug-resistant microorganisms (MDROs) infections.
Methods: Retrospective study conducted between March and June 2020.
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 emerged in China at the end of 2019. Because of the severe immunomodulation and lymphocyte depletion caused by this virus and the subsequent administration of drugs directed at the immune system, we anticipated that patients might experience fungal superinfection. We collected data from 186 patients who had coronavirus disease-associated pulmonary aspergillosis (CAPA) worldwide during March-August 2020.
View Article and Find Full Text PDFObjectives: Information on the recently COVID-19-associated pulmonary aspergillosis (CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU patients with coronavirus disease 2019 (COVID-19), and review the published literature from Western countries.
Methods: Prospective study (March to May, 2020) that included all COVID-19 patients admitted to a tertiary hospital.